Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PRQR)

ProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfolio

GlobeNewswire 1 day ago

ProQR Announces Year End 2023 Operating and Financial Results

GlobeNewswire March 13, 2024

ProQR Announces Japanese Axiomer(TM) Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

GlobeNewswire February 15, 2024

ProQR Highlights New Platform Data from Presentation on Axiomer(TM) RNA Editing Technology at Deaminet 2024

GlobeNewswire January 19, 2024

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer(TM) RNA Editing Collaboration

GlobeNewswire January 5, 2024

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

GlobeNewswire December 8, 2023

ProQR Announces Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 7, 2023

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

GlobeNewswire November 6, 2023

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

GlobeNewswire September 28, 2023
View More News ››

Opinion & Analysis (NDAQ:PRQR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PRQR)

ProQR Achieves Successful Defense of New Challenge to its Ax

News; $PRQR ProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioLEIDEN, Netherlands @ CAMBRIDGE, Mass...
whytestocks - 20 hours ago

PRQR ....In PB mode need to hold support at $2.57

and rally or ....it's done for the day
Iseneschal - December 22, 2022

PRQR ....early a.m runner

On watch
Iseneschal - December 22, 2022

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021
View more Bullboard ››

Xcyte Digital Corp.

Xcyte Digital Corp.

Xcyte Digital is a virtual event company focused on simplifying the event hosting industry and expanding event hosting ...
View More »